3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
6
Hematologic Neoplasms
5
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Motor Activity
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Anxiety Disorders
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Interventions
pembrolizumab
3
Nivolumab
3
Ipilimumab
3
Cyclophosphamide
3
Radiosurgery
2
MART-1 Antigen
2
CTLA-4 Antigen
2
ulixertinib
1
sotrastaurin
1
siremadlin
1
relatlimab
1
pentetreotide
1
oblimersen
1
incomplete Freund's adjuvant
1
fotemustine
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
defactinib
1
binimetinib
1
benzamide
1
aldesleukin
1
aflibercept
1
Valacyclovir
1
Toll-Like Receptor 1
1
TYRP1 protein, human
1
Sunitinib
1
Standard of Care
1
RO5126766
1
RNA, Messenger
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Uveal Melanoma
×
Standard of Care
×
Clear all
NCT05266430
2023-08-09
IL
Aura Biosciences
Terminated
2 enrolled